Promimic AB (PRO) Fair Value & Analysis
Healthcare · SE · Market cap 215M SEK
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price −29.9% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 9.73 – kr 21.11 · fair‑value band kr 10.56 – kr 17.60 · the kr 10.30 price screens below the kr 14.08 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Promimic AB (PRO) currently trades at kr 10.30, while our model-based Fair Value estimate is kr 14.08 — implying the stock looks roughly 36.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Promimic AB generated revenue of 51.1M SEK at a net margin of -17.2%. Revenue declined 12.9% year over year. It earns a return on equity of -13.6%. The balance sheet holds a net cash position of 20.6M SEK. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Promimic AB (publ) engages in the manufacturing, marketing, and sale of biomaterials for improved osseointegration in the orthopedic and dental implants markets in Sweden. It offers HAnano surface which combines several properties that are known to improve osseointegration into one unique surface modification; and nano-sized crystalline powder or suspension hydroxyapatite can be used in r and d, as an ingredient in bone substitutes or as a chromatography material. The company was incorporated in 2004 and is headquartered in Mölndal, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Promimic AB reported revenue of kr 44.4M in FY2025 versus kr 8.1M in FY2021, a compound +53.2%/yr. Reported net income was −kr 8.8M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Promimic AB (PRO) undervalued?
What is the fair value of PRO?
What is the quality score of PRO?
What is the revenue of Promimic AB (PRO)?
What is the net profit margin of PRO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.